AZD2014

Phase 2Small molecule

AstraZeneca

AZD2014 is one of 27 small molecule programs targeting Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Breast CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Adenocard

Astellas

Preclinical

2 2

Blenoxane

Bristol-Myers Squibb

Preclinical

1 3

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 4

Duragesic

CCephalon

Preclinical

1 5

AZD2014

AstraZeneca

Phase 2

4 6

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

1 7

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 8

Tianeptine

Pfizer

Preclinical

1 9

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 10

Bisphosphonate

Amgen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast Cancer4 trials

Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02599714·54 enrolled

AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01597388·99 enrolled

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

Active, not recruiting·UUNICANCER·Phase 2·NCT02299999·1,460 enrolled

Show 1 more trial

A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer

Completed·QQueen Mary University of London·Phase 2·NCT02216786·333 enrolled

Meningioma2 trials

Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas

Unknown status·MMassachusetts General Hospital·Phase 2·NCT03071874·28 enrolled

AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas

Completed·MMassachusetts General Hospital·Phase 2·NCT02831257·18 enrolled

Chemotherapy1 trial

Phase II Trial of AZD2014 in TSC1/2 Mutated or TSC1/2 Null GC Patients as Second-line Chemotherapy

Terminated·SSamsung Medical Center·Phase 2·NCT03082833·1 enrolled

Gastric Adenocarcinoma1 trial

Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy

Terminated·SSamsung Medical Center·Phase 2·NCT02449655·27 enrolled

Advanced Cancers1 trial

A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers

Unknown status·QQueen Mary University of London·Phase 1/2·NCT02583542·118 enrolled

10 more indications

Prostate Cancer1 trial

Investigating the Effects of AZD2014 Therapy Given Prior to Radical Prostatectomy in Men With High Risk Prostate Cancer

Completed·—·Phase 1·NCT02064608·23 enrolled

Efficacy1 trial

Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01026402·172 enrolled

Glioblastoma Multiforme1 trial

mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme

Completed·CCanadian Cancer Trials Group·Phase 1·NCT02619864·15 enrolled

Endometrial Carcinoma1 trial

Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)

Unknown status·CCentre Leon Berard·Phase 1/2·NCT02730923·72 enrolled

Single Dose1 trial

Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02640755·4 enrolled

Renal Cancer1 trial

A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer

Terminated·QQueen Mary University of London·Phase 2·NCT01793636·49 enrolled

Metastatic NSCLC1 trial

SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients

Completed·UUNICANCER·Phase 2·NCT02117167·999 enrolled

Second-line Therapy1 trial

Trial of Single Agent AZD2014 in RICTOR Amplified GC Patients as Second-line Therapy

Terminated·SSamsung Medical Center·Phase 2·NCT03061708·1 enrolled

Diffuse Large B-Cell Lymphoma1 trial

AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Withdrawn· AstraZeneca logo

AstraZeneca·Phase 1·NCT02780830

Advanced Solid Malignancies1 trial

Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02398747·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 19 trial records for AZD2014. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD2014 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD2014. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AstraZeneca

AZD2014

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Breast Cancer4 trials

Meningioma2 trials

Chemotherapy1 trial

Gastric Adenocarcinoma1 trial

Advanced Cancers1 trial

Prostate Cancer1 trial

Efficacy1 trial

Glioblastoma Multiforme1 trial

Endometrial Carcinoma1 trial

Single Dose1 trial

Renal Cancer1 trial

Metastatic NSCLC1 trial

Second-line Therapy1 trial

Diffuse Large B-Cell Lymphoma1 trial

Advanced Solid Malignancies1 trial

References

Drug Info

Quick Facts

Related News